Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Abstract:
GeneSegues, Inc., a leader in drug delivery at the sub-50 nanometer scale, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent covering the company's proprietary drug delivery technology (EP Application No. 01920161.5). This patent stems from pioneering work by the company in delivering therapeutic molecules such as oligonucleotides and plasmid DNA to target cells using nanocapsules of less than 50 nanometers in diameter. Compositions of this size impart significant advantages including entering the target cell without triggering defense mechanisms that can degrade the capsule and drug.

GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Minneapolis, MN | Posted on March 6th, 2012

"We are gratified that the EPO has recognized the importance and patentability of our discoveries in nonviral technologies that can take advantage of efficient lipid raft pathways into the target cell," said Gretchen Unger, Ph.D., Chief Scientific Officer and founder of GeneSegues. "This patent covers a broad and significant technology platform which we are continuing to develop with collaborators across a range of applications including cancer, liver, and infectious diseases."

The new patent includes claims covering compositions of sub-50 nanometer capsules and methods of formulation. The composition claims cover sub-50 nanometer capsules that consist of a substitutable biopolymer ligand shell which can actively target the composition to any desired cell type, and can encapsulate large or small molecule drug cargo. The method claims cover the processes for formulating the nanocapsules with a novel design that is both versatile and scalable.

####

About GeneSegues, Inc.
GeneSegues is a biopharmaceutical company focused on applying its novel drug delivery technology to produce breakthrough nucleic acid-based therapeutics and vaccines for the treatment and prevention of serious diseases. The company’s sub-50 nanometer (‘s50’) capsule technology addresses the series of biological barriers that prevent nucleic acids from reaching the therapeutically-important cytoplasm and nucleus of the target cell.

For more information, please click here

Contacts:
Gretchen Unger, Ph.D.
Chief Scientific Officer
GeneSegues, Inc.
952.443.3798

Copyright © GeneSegues, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Patents/IP/Tech Transfer/Licensing

Silicon Valley-Based Foresight Valuation Launches STR-IP™, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014

Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014

Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014

First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE